• Something wrong with this record ?

In-vitro Evaluation of Triazine Scaffold for Anticancer Drug Development: A Review

P. Dubey, DP. Pathak, F. Ali, G. Chauhan, V. Kalaiselvan

. 2024 ; 21 (2) : e170723218813. [pub] -

Language English Country United Arab Emirates

Document type Journal Article, Review

INTRODUCTION: The widespread importance of the synthesis and modification of anticancer agents has given rise to many numbers of medicinal chemistry programs. In this regard, triazine derivatives have attracted attention due to their remarkable activity against a wide range of cancer cells. This evaluation covers work reports to define the anticancer activity, the most active synthesized compound for the target, the SAR and, when described, the probable MOA besides similarly considered to deliver complete and target-pointed data for the development of types of anti-tumour medicines of triazine derivatives. Triazine scaffold for the development of anticancer analogues. Triazine can also relate to numerous beneficial targets, and their analogues have auspicious in-vitro and in-vivo anti-tumour activity. Fused molecules can improve efficacy, and drug resistance and diminish side effects, and numerous hybrid molecules are beneath diverse stages of clinical trials, so hybrid derivatives of triazine may offer valuable therapeutic involvement for the dealing of tumours. OBJECTIVE: The objective of the recent review was to summarize the recent reports on triazine as well as its analogues with respect to its anticancer therapeutic potential. CONCLUSION: The content of the review would be helpful to update the researchers working towards the synthesis and designing of new molecules for the treatment of various types of cancer disease with the recent molecules that have been produced from the triazine scaffold. Triazine scaffolds based on 1,3,5-triazine considerably boost molecular diversity levels and enable covering chemical space in key medicinal chemistry fields.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014605
003      
CZ-PrNML
005      
20240905133939.0
007      
ta
008      
240725s2024 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1570163820666230717161610 $2 doi
035    __
$a (PubMed)37461340
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a Dubey, Pragya $u Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, Mehrauli- Badarpur Road, Sector 3, Pushp Vihar, New Delhi, 110017, India
245    10
$a In-vitro Evaluation of Triazine Scaffold for Anticancer Drug Development: A Review / $c P. Dubey, DP. Pathak, F. Ali, G. Chauhan, V. Kalaiselvan
520    9_
$a INTRODUCTION: The widespread importance of the synthesis and modification of anticancer agents has given rise to many numbers of medicinal chemistry programs. In this regard, triazine derivatives have attracted attention due to their remarkable activity against a wide range of cancer cells. This evaluation covers work reports to define the anticancer activity, the most active synthesized compound for the target, the SAR and, when described, the probable MOA besides similarly considered to deliver complete and target-pointed data for the development of types of anti-tumour medicines of triazine derivatives. Triazine scaffold for the development of anticancer analogues. Triazine can also relate to numerous beneficial targets, and their analogues have auspicious in-vitro and in-vivo anti-tumour activity. Fused molecules can improve efficacy, and drug resistance and diminish side effects, and numerous hybrid molecules are beneath diverse stages of clinical trials, so hybrid derivatives of triazine may offer valuable therapeutic involvement for the dealing of tumours. OBJECTIVE: The objective of the recent review was to summarize the recent reports on triazine as well as its analogues with respect to its anticancer therapeutic potential. CONCLUSION: The content of the review would be helpful to update the researchers working towards the synthesis and designing of new molecules for the treatment of various types of cancer disease with the recent molecules that have been produced from the triazine scaffold. Triazine scaffolds based on 1,3,5-triazine considerably boost molecular diversity levels and enable covering chemical space in key medicinal chemistry fields.
650    12
$a triaziny $x farmakologie $x chemie $x terapeutické užití $7 D014227
650    12
$a antitumorózní látky $x farmakologie $x chemie $x terapeutické užití $7 D000970
650    _2
$a lidé $7 D006801
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a vyvíjení léků $x metody $7 D000076722
650    _2
$a zvířata $7 D000818
650    _2
$a léky antitumorózní - screeningové testy $7 D004354
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Pathak, Dharam Pal $u Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, Mehrauli- Badarpur Road, Sector 3, Pushp Vihar, New Delhi, 110017, India
700    1_
$a Ali, Faraat $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, Hradec Králové 500 05, Czech Republic $u Department of Licensing and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority, Gaborone, Botswana $1 https://orcid.org/0000000214384223
700    1_
$a Chauhan, Garima $u Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, Mehrauli- Badarpur Road, Sector 3, Pushp Vihar, New Delhi, 110017, India
700    1_
$a Kalaiselvan, Vivekanandan $u Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23, Raj Nagar, Ghaziabad 201002, India
773    0_
$w MED00008818 $t Current drug discovery technologies $x 1875-6220 $g Roč. 21, č. 2 (2024), s. e170723218813
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37461340 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133933 $b ABA008
999    __
$a ok $b bmc $g 2144024 $s 1226471
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 21 $c 2 $d e170723218813 $e - $i 1875-6220 $m Current drug discovery technologies $n Curr Drug Discov Technol $x MED00008818
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...